Home
Frode Steingrimsen Berven's picture

Frode Steingrimsen Berven

Professor, Deputy Head of Department
IBM: PROBE
  • E-mailFrode.Berven@uib.no
  • Phone+47 55 58 67 43+47 991 63 866
  • Visitor Address
  • Postal Address
    Postboks 7804

Dr. Frode S. Berven (Ph.D.) is the head of the Proteomics Unit at the University of Bergen.

Berven completed his Masters degree at Department of Molecular Biologi, UiB, Ph.D. in bioinformatics at the Department of Informatics, UiB, and post doctor at the Institute of Medicine, UiB, and at the Proteomics Platform at the Broad Institute of MIT and Harvard.

He is working in the field of mass spectrometry based quantitative proteomics with emphaisis on biomarker disocovery and verification in cerebrospinal fluid of patients with multiple sclerosis.

1.      A    Berle M, Wester KG, Ulvik RJ, Kroksveen AC, Haaland OA, Amiry-Moghaddam M, Berven FS, Helland CA. “Arachnoid cysts do not contain cerebrospinal fluid: A comparative chemical analysis of arachnoid cyst fluid and cerebrospinal fluid in adults.” Cerebrospinal fluid research,  2010 June 10;7:8.

2.      A    Rajalahti T, Kroksveen AC, Arneberg R, Berven FS, Vedeler CA, Myhr KM, Kvalheim OM. “A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis.” Journal of Proteome Research, 2010 July 2;9(7):3608-20.

3.      A    Berven FS. Ahmad R. Clauser K. Carr SA. “Optimizing performance of glycopeptides capture for plasma proteomics”. Journal of Proteome Research, 2010 April 5;9(4):1706-15.

4.      A    Teunissen CE, Tumani HT, Bennett JL, Berven FS, ++, Deisenhammer F, Giovannoni G. “Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Multiple Sclerosis, 2010; 16(2) 129-32.

5.      A    Teunissen CE, Tumani HT, JL. Bennett, FS. Berven, ++, M. Comabella, D., C. Wolf, H. Tumani, B. Hemmer, F. Deisenhammer. “A consensus protocol for standardisation of CSF sampling and biobanking”. Neurology, 2009;73;1914-1922.

6.      A    Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK, Altintas A, Bennett JL, Berven FS, Petzold A, Rajda C, Rejdak K, van Pesch V, Waubant E. “Cerebrospinal fluid biomarkers in multiple sclerosis”. Neurobiol Dis. 2009 Aug;35(2):117-27.

7.      A    Rajalahti T. Arneberg R. Berven FS. Myhr KM. Ulvik RJ. Kvalheim OM. “Biomarker discovery in mass spectral profiles by means of selectivity ratio plot”. Chemometrics and Intelligent Laboratory Systems. 2008 August

8.      A    Målen, H. Berven, FS. Søfteland, T. Arntzen, ØM. D’Santos, C. Wiker, H. “Membrane- and membrane associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies”. Proteomics. 2008 may 8(9) 1859-70.

9.      A    Rajalahti, T. Arneberg, R. Berven, FS. Kroksveen, AC. Berle, M. Flikka, K. Myhr, KM. Vedeler, C. Kvalheim, OM. Ulvik, RJ. “Pretreatment of mass spectral profiles: Application to proteomic data”. Analytical Chemistry. 2007 August 79 (18) 7014-7026.

10.   A    Berven, FS. Kroksveen, AC. Berle, M. Flikka, K. Myhr, KM. Vedeler, C. Arneberg, R. Rajalahti, T. Kvalheim, OM. Ulvik, RJ. “Pre-analytical influence on the low molecular weight cerebro spinal fluid proteome”. Proteomics Clinical Applications. 2007 July 1(7) 699-711. Selected as an “In this issue” highlighted article.

11.   A    Målen, H. Berven, FS. Fladmark, K. Wiker, H. “Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv”.  Proteomics. 2007 May 7(10) 1702-18. Selected as an “In this issue” highlighted article.

12.   A    Aukrust I, Evensen L, Hollas H, Berven F, Atkinson RA, Trave G, Flatmark T, Vedeler A. “Engineering, biophysical  characterization and binding properties of a soluble mutant form of annexin A2 domain IV that adopts a partially folded conformation”. Journal of molecular biology. 2006 Oct 20;363(2):469-81.

13.   A    Berven FS, Flikka K, Berle M, Vedeler C, Ulvik RJ. “Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis”. Curr Pharm Biotechnol. 2006 Jun;7(3):147-58. Review.

14.   A    Berven, FS. Karlsen, OA. Straume, AH. Flikka, K. Murrell, JC. Lillehaug, JR. Fjellbirkeland, A. Eidhammer, I. Jensen, HB. ”Analysing the outer membrane subproteome of Methylococcus capsulatus (Bath) using proteomics and novel biocomputing tools”. Arch Microbiol. 2006 Feb;184(6):362-77. Epub 2005 Nov 26.

15.   A    Karlsen, OA. Ramsevik, L. Bruseth, LJ. Larsen O. Brenner, A. Berven, FS. Jensen, HB. Lillehaug, JR. “Characterization of a prokaryotic haemerythrin from the methanotrophic bacterium Methylococcus capsulatus (Bath)”. FEBS journal 2005, Volume 272, Issue10, Pages 2428-2440.

16.   A    Berven, FS. Flikka, K. Jensen, HB. Eidhammer, I. “BOMP: a program to predict integral b-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria”. Nucleic Acids Research 2004, Volume 32, Web Server Issue, Pages W394-399.

17.   A    Karlsen, OA. Berven, FS. Stafford, GP. Larsen, O. Murrell, JC. Jensen, HB. Fjellbirkeland, A. “The surface-associated and secreted MopE protein of Methylococcus capsulatus (Bath) responds to changes in the concentration of copper in the growth medium”. Applied Environmental Microbiology, April 2003, Volume 69, Issue 4, Pages 2386-2388.

18.   A    Berven, FS. Karlsen OA. Murrell, JC. Jensen, HB. “Multiple polypeptide forms observed in two-dimensional gels of Methylococcus capsulatus (Bath) polypeptides are generated during the separation procedure”. Electrophoresis, February 2003, Volume 24, Issue 4, Pages 757-761.

 

  • Show author(s) 2020. The progression of acute myeloid leukemia from first diagnosis to chemoresistant relapse: A comparison of proteomic and phosphoproteomic profiles. Cancers. 1-13.
  • Show author(s) 2020. The extracellular bone marrow microenvironment — a proteomic comparison of constitutive protein release by in vitro cultured osteoblasts and mesenchymal stem cells. Cancers.
  • Show author(s) 2020. The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. Cancers.
  • Show author(s) 2020. Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. Cancers.
  • Show author(s) 2020. Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis. Clinical Proteomics. 1-21.
  • Show author(s) 2020. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging.
  • Show author(s) 2020. Anatomy and evolution of database search engines-a central component of mass spectrometry based proteomic workflows. Mass spectrometry reviews (Print).
  • Show author(s) 2019. The capacity of long-term in vitro proliferation of acute myeloid leukemia cells supported only by exogenous cytokines is associated with a patient subset with adverse outcome. Cancers. 1-22.
  • Show author(s) 2019. Quantitative proteomic analyses of CD4+ and CD8+ T cells reveal differentially expressed proteins in multiple sclerosis patients and healthy controls.
  • Show author(s) 2019. Quantitative proteomic analyses of CD4+ and CD8+ T cells reveal differentially expressed proteins in multiple sclerosis patients and healthy controls . Clinical Proteomics. 1-18.
  • Show author(s) 2019. Proteomic profiling of primary human acute myeloid leukemia cells does not reflect their constitutive release of soluble mediators. Proteomes. 1-10.
  • Show author(s) 2019. Proteome and phosphoproteome changes associated with prognosis in acute myeloid leukemia. bioRxiv - the preprint server for biology.
  • Show author(s) 2019. Protein post-translational modification crosstalk in acute myeloid leukemia calls for action. Current Medicinal Chemistry. 5317-5337.
  • Show author(s) 2019. Essential Features and Use Cases of the Cerebrospinal Fluid Proteome Resource (CSF-PR). 15 pages.
  • Show author(s) 2019. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
  • Show author(s) 2019. Effect of disease-associated SLC9A9 mutations on protein–protein interaction networks: implications for molecular mechanisms for ADHD and autism. ADHD Attention Deficit and Hyperactivity Disorders. 91-105.
  • Show author(s) 2019. Detecting single amino acids and small peptides by combining isobaric tags and peptidomics. European Journal of Mass Spectrometry.
  • Show author(s) 2019. Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli. BMC Nephrology. 1-12.
  • Show author(s) 2019. A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Science Translational Medicine.
  • Show author(s) 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) 2018. Proteomic profiling of lung immune cells reveals dysregulation of phagocytotic pathways in female-dominated molecular COPD phenotype. Respiratory Research.
  • Show author(s) 2018. Proteomic profiling of T cells from multiple sclerosis patients and healthy controls.
  • Show author(s) 2018. Proteomic profiling of CD4+ and CD8+ T cells from multiple sclerosis patients and healthy controls.
  • Show author(s) 2018. Proteomic profiling of CD4+ and CD8+ T cells from multiple sclerosis patients and healthy controls.
  • Show author(s) 2018. Proteomic profiling of CD4+ T cells from MS patients show increased activity of T cell activation pathways (compared to healthy controls) .
  • Show author(s) 2018. Long-term smoking alters abundance of over half of the proteome in bronchoalveolar lavage cell in smokers with normal spirometry, with effects on molecular pathways associated with COPD. Respiratory Research.
  • Show author(s) 2018. Development and Use of Mass Spectrometry Based Quantitative Proteomics Assays for Multiple Sclerosis Biomarker Candidates.
  • Show author(s) 2017. Rethinking the role of osteopontin in human acute myeloid leukemia. Leukemia and Lymphoma. 1494-1497.
  • Show author(s) 2017. Quantitative proteomics analysis reveals perturbation of lipid metabolic pathways in the liver of Atlantic cod (Gadus morhua) treated with PCB 153. Aquatic Toxicology. 19-28.
  • Show author(s) 2017. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. Espert Review of Proteomics. 649-663.
  • Show author(s) 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) 2017. Integrative transcriptome and proteome analysis reveals perturbation of lipid metabolic pathways in the liver of Atlantic cod (Gadus morhua) treated with PCB 153.
  • Show author(s) 2017. In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
  • Show author(s) 2017. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy. Clinical Proteomics.
  • Show author(s) 2017. Fast hyperbaric decompression after heliox saturation altered the brain proteome in rats. PLOS ONE. 1-16.
  • Show author(s) 2017. Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression. Scientific Reports. 1-15.
  • Show author(s) 2017. Anatomy and evolution of database search engines—a central component of mass spectrometry based proteomic workflows. Mass spectrometry reviews (Print). 292-306.
  • Show author(s) 2017. 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
  • Show author(s) 2016. Visualization, Inspection and Interpretation of Shotgun Proteomics Identification Results. 10 pages.
  • Show author(s) 2016. Using Proteomics Bioinformatics Tools and Resources in Proteogenomic Studies. Advances in Experimental Medicine and Biology. 65-75.
  • Show author(s) 2016. The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
  • Show author(s) 2016. Tandem Mass Spectrum Sequencing: An Alternative to Database Search Engines in Shotgun Proteomics. 10 pages.
  • Show author(s) 2016. Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
  • Show author(s) 2016. Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
  • Show author(s) 2016. Quantitative analyses of the hepatic proteome of methylmercury-exposed Atlantic cod (Gadus morhua) suggest oxidative stress-mediated effects on cellular energy metabolism. BMC Genomics. 1-15.
  • Show author(s) 2016. Proteomic Analysis of Minimally Damaged Renal Tubular Tissue from Two-Kidney-One-Clip Hypertensive Rats Demonstrates Extensive Changes Compared to Tissue from Controls. Nephron. 70-80.
  • Show author(s) 2016. Proteome and deglycopeptide analyses of neurologically healthy and multiple sclerosis affected cerebrospinal fluid: Mass spectrometry experiments, literature mining and data sharing .
  • Show author(s) 2016. Practical considerations for omics experiments in biomedical sciences. Current Pharmaceutical Biotechnology. 105-114.
  • Show author(s) 2016. Mass spectrometry-based proteome quantification in leukemic cells from acute myeloid leukemia patients.
  • Show author(s) 2016. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
  • Show author(s) 2016. Interpretation of Quantitative Shotgun Proteomic Data. 14 pages.
  • Show author(s) 2016. Integrative -omics analyses reveal perturbation of lipid metabolic pathways in the liver of Atlantic cod (Gadus morhua) exposed to the persistent organic pollutant PCB 153.
  • Show author(s) 2016. Integrated analysis of transcriptome and proteome reveals perturbation of lipid metabolic pathways in the liver of Atlantic cod (Gadus morhua) treated with the persistent organic pollutant PCB 153 .
  • Show author(s) 2016. Glycopeptide analysis and glycan structure inference from mass spectrometry data-Investigating the potential of computational glycan structure analysis in biomedical research.
  • Show author(s) 2016. Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients. Current Pharmaceutical Biotechnology. 52-70.
  • Show author(s) 2016. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. Journal of Proteomics. 214-225.
  • Show author(s) 2016. Exploring the potential of public proteomics data. Proteomics. 214-225.
  • Show author(s) 2016. Database Search Engines: Paradigms, Challenges and Solutions. 10 pages.
  • Show author(s) 2016. CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. Molecular & Cellular Proteomics. 300-309.
  • Show author(s) 2016. A Simple Workflow for Large Scale Shotgun Glycoproteomics. 12 pages.
  • Show author(s) 2015. Viewing the proteome: How to visualize proteomics data? Proteomics. 1341-1355.
  • Show author(s) 2015. Use of ENCODE resources to characterize novel proteoforms and missing proteins in the human proteome. Journal of Proteome Research. 603-608.
  • Show author(s) 2015. The EuPA Biobank Initiative: Meeting the future challenges of biobanking in proteomics & systems medicine. Journal of Proteomics. 414-416.
  • Show author(s) 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
  • Show author(s) 2015. PeptideShaker enables reanalysis of MS-derived proteomics data sets. Nature Biotechnology. 22-24.
  • Show author(s) 2015. In vitro transcription/translation system: A versatile tool in the search for missing proteins. Journal of Proteome Research. 3441-3451.
  • Show author(s) 2015. Erratum to: Association of chromosome 19 to lung cancer genotypes and phenotypes. Cancer Metastasis Review. 227-227.
  • Show author(s) 2015. Distributed and interactive visual analysis of omics data. Journal of Proteomics. 78-82.
  • Show author(s) 2015. Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
  • Show author(s) 2015. Association of chromosome 19 to lung cancer genotypes and phenotypes. Cancer Metastasis Review. 217-226.
  • Show author(s) 2014. Shedding light on black boxes in protein identification. Proteomics. 1001-1005.
  • Show author(s) 2014. Proteomic analysis of formalin-fixed paraffin-embedded glomeruli suggests depletion of glomerular filtration barrier proteins in two-kidney one-clip hypertensive rats. Nephrology, Dialysis and Transplantation. 11 pages.
  • Show author(s) 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Show author(s) 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Show author(s) 2014. Label-free proteomics analysis of plasma to discover proteins with differential abundance between multiple sclerosis patients and controls.
  • Show author(s) 2014. Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines. Journal of Proteome Research. 191-199.
  • Show author(s) 2014. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Molecular & Cellular Proteomics. 3152-3163.
  • Show author(s) 2014. Exploring the human plasma proteome for humoral mediators of remote ischemic preconditioning - A word of caution. PLOS ONE.
  • Show author(s) 2014. Establishment and usage of quantitative brain proteomics to investigate the role of Peli1 E3 ubiquitin ligase in the EAE mouse model of multiple sclerosis.
  • Show author(s) 2014. Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
  • Show author(s) 2014. Carboxyl-ester lipase maturity-onset diabetes of the young disease protein biomarkers in secretin-stimulated duodenal juice. Journal of Proteome Research. 521-530.
  • Show author(s) 2014. Bioinformatics for Proteomics: Opportunities at the interface between the scientists, their experiments and the community. 10 pages.
  • Show author(s) 2013. Quantitative proteomics comparison of arachnoid cyst fluid and cerebrospinal fluid collected perioperatively from arachnoid cyst patients. Fluids and Barriers of the CNS.
  • Show author(s) 2013. Proteomic analysis of outer and juxtamedullary cortex of non-clipped kidneys in 2K1C hypertensive rats. The FASEB Journal. 1 pages.
  • Show author(s) 2013. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. Journal of Proteomics. 312-325.
  • Show author(s) 2013. Developments in biobanking workflow standardization providing sample integrity and stability. Journal of Proteomics. 38-45.
  • Show author(s) 2013. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis. 1802-1809.
  • Show author(s) 2013. Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium. Journal of Proteome Research. 134-149.
  • Show author(s) 2012. Use of stable isotope dimethyl labeling coupled to selected reaction monitoring to enhance throughput by multiplexing relative quantitation of targeted proteins. Analytical Chemistry. 4999-5006.
  • Show author(s) 2012. Minimization of side reactions during Lys Tag derivatization of C-terminal lysine peptides. Analytica Chimica Acta. 101-107.
  • Show author(s) 2012. Mass spectrometry-based proteomics of human cerebrospinal fluid Biomarker discovery and verification in multiple sclerosis.
  • Show author(s) 2012. Glycoproteomics in Human Cerebrospinal Fluid Mapping the CSF Proteome, and Biomarker Discovery and Qualification in Multiple Sclerosis.
  • Show author(s) 2012. Global proteomic analyses of fish leukocytes during pathogen infections.
  • Show author(s) 2012. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurologica Scandinavica. 90-96.
  • Show author(s) 2011. compomics-utilities: an open-source Java library for computational proteomics. BMC Bioinformatics. 5 pages.
  • Show author(s) 2011. The field of proteomics in Norway. Public Service Review : European Union.
  • Show author(s) 2011. SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. Proteomics. 996-999.
  • Show author(s) 2011. Proteomics of human cerebrospinal fluid: Discovery and verification of disease biomarker candidates in neurodegenerative diseases using quantitative proteomics. Journal of Proteomics. 371-388.
  • Show author(s) 2011. Proteomics in Cerebrospinal fluid: Finding proteins highly enriched in CSF, proteins influenced by the rostro-caudal gradient, and biomarker verification in Multiple Sclerosis.
  • Show author(s) 2011. Protein profiling reveals inter-individual protein homogeneity of arachnoid cyst fluid and high qualitative similarity to cerebrospinal fluid. Fluids and Barriers of the CNS.
  • Show author(s) 2011. Methylococcus capsulatus (Bath): From Genome to Protein Function, and Vice Versa. Methods in Enzymology. 63-79.
  • Show author(s) 2011. METHANOTROPH OUTER MEMBRANE PREPARATION. Methods in Enzymology. 167-176.
  • Show author(s) 2011. IsobariQ: Software for isobaric quantitative proteomics using IPTL, iTRAQ and TMT.
  • Show author(s) 2011. IsobariQ: Software for Isobaric Quantitative Proteomics using IPTL, iTRAQ, and TMT. Journal of Proteome Research. 913-920.
  • Show author(s) 2011. A proteomics study of Cerebrospinal fluid in relation to biomarker discovery and verification in Multiple Sclerosis, with emphasis on the effect of pre-analytical factors.
  • Show author(s) 2011. A monoclonal antibody distinguishes between two IgM heavy chain isotypes in Atlantic salmon and brown trout: Protein characterization, 3D modeling and epitope mapping. Molecular Immunology.
  • Show author(s) 2010. Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Multiple Sclerosis. 129-132.
  • Show author(s) 2010. Optimizing performance of glycopeptide capture for plasma proteomics. Journal of Proteome Research. 1706-1715.
  • Show author(s) 2010. Arachnoid cysts do not contain cerebrospinal fluid: A comparative chemical analysis of arachnoid cyst fluid and cerebrospinal fluid in adults. Cerebrospinal Fluid Research.
  • Show author(s) 2010. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.
  • Show author(s) 2010. A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin. 1-12.
  • Show author(s) 2009. Discovery of novel diagnostic biomarker candidates for multiple sclerosis through clinical proteomics.
  • Show author(s) 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease. 117-127.
  • Show author(s) 2009. Biomarker discovery in mass spectral profiles by means of selectivity ratio plot. Chemometrics and Intelligent Laboratory Systems. 35-48.
  • Show author(s) 2009. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 1914-1922.
  • Show author(s) 2008. Membrane- and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies.
  • Show author(s) 2008. Membrane- and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies.
  • Show author(s) 2008. Membrane- and membrane associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics. 1859-1870.
  • Show author(s) 2008. Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
  • Show author(s) 2008. Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
  • Show author(s) 2007. Target projection and proper data pre-treatment for the analysis of proteomic profiles.
  • Show author(s) 2007. Proteomics applied on cerebrospinal fluid, with focus on methods development and candidate biomarker discovery in multiple sclerosis patients.
  • Show author(s) 2007. Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry. 7014-7026.
  • Show author(s) 2007. Preteatment of Mass Spectral Profiles: Application to proteomic data.
  • Show author(s) 2007. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS - Clinical Applications. 699-711.
  • Show author(s) 2007. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics. 1702-1718.
  • Show author(s) 2007. Analysis of Proteomic Profiles.
  • Show author(s) 2006. Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis. Current Pharmaceutical Biotechnology. 147-158.
  • Show author(s) 2006. Late breaker: Revealing the secreted proteome of Mycobacterium tuberculosis H37Rv.
  • Show author(s) 2006. Engineering, biophysical characterisation and binding properties of a soluble mutant form of annexin A2 domain IV that adopts a partially folded conformation. Journal of Molecular Biology (JMB). 469-481.
  • Show author(s) 2006. Comparing the protein identifications obtained using two-dimensional gel electrophoresis or liquid chromatography mass spectrometry on the secreted proteome of Mycobacterium tuberculosis.
  • Show author(s) 2006. Analysing the outer membrane subproteome of Methylococcus capsulatus (Bath) using proteomics and novel biocomputing tools. Archives of Microbiology. 362-377.
  • Show author(s) 2005. Characterisation of a prokaryotic hemerythrin from the methanotrophic bacterium Methylococcus capsulatus (Bath). The FEBS Journal. 2428-2440.
  • Show author(s) 2005. Analysing the outer membrane and subproteome of Methylococcus capsulatus (Bath) using proteomics and bioinformatics.
  • Show author(s) 2004. Methylococcus capsulatus (Bath); Molecular analyses of a surface exposed heteromultimeric protein complex.
  • Show author(s) 2004. BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria. Nucleic Acids Research. W394-W399.
  • Show author(s) 2003. The surface-associated and secreted MopE protein of Methylococcus capsulatus (Bath) responds to changes in the concentration of copper in the growth medium. Applied and Environmental Microbiology. 2386-2388.
  • Show author(s) 2003. The expression of the surface associated MopE protein of Methylococcus capsulatus (Bath) is regulated by the concentration of copper in the growth medium.
  • Show author(s) 2003. Proteome studies on the methanotrophic bacterium Methylococcus capsulatus (Bath).
  • Show author(s) 2003. Multiple polypeptide forms observed in twodimensional gels of Methylococcus capsulatus (Bath)polypeptides are generated during the separation procedure.
  • Show author(s) 2003. Multiple polypeptide forms observed in two-dimensional gels of Methylococcus capsulatus (Bath) polypeptides are generated during the separation procedure. Electrophoresis. 757-761.
  • Show author(s) 2003. Identification of the ORF upstream of MopE in Methylococcus capsulatus.
  • Show author(s) 2003. Differential expression in sMMO and pMMO producing cells of Methylococcus capsulatus (Bath).
  • Show author(s) 2002. Initial proteome studies on Methylococcus capsulatus (Bath).
  • Show author(s) 2002. Initial proteome studies of Methylococcus capsulatus (Bath).
  • Show author(s) 2002. Characterization of copper-repressible extracellular protein of Methylococcus capsulatus (Bath).
  • Show author(s) 2002. Analysis of two IgM isotypes in Atlantic salmon and brown trout. Molecular Immunology. 313-321.
  • Show author(s) 2001. The establishement and use of 2-dimensional gel electrophoresis in proteome studies of Methylococcus capsulatus(Bath).

More information in national current research information system (CRIStin)

Research groups